Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer (vol 18, pg 758, 2012)

被引：0
|
作者：
Sun, Jessica D.
Liu, Qian
Wang, Jingli
Ahluwalia, Dharmendra
Ferraro, Damien
Wang, Yan
Duan, Jian-Xin
Ammons, W. Steve
Curd, John G.
Matteucci, Mark D.
Hart, Charles P.
机构：
来源：
CLINICAL CANCER RESEARCH | 2024年 / 30卷 / 10期
关键词：
D O I：
10.1158/1078-0432.CCR-24-1058
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2287 / 2287
页数：1
相关论文
共 50 条
  • [21] Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models
    Liapis, V
    Zinonos, I
    Labrinidis, A.
    Hay, S.
    Ponomarev, V
    Panagopoulos, V
    Zysk, A.
    DeNichilo, M.
    Ingman, W.
    Atkins, G. J.
    Findlay, D. M.
    Zannettino, A. C. W.
    Evdokiou, A.
    CLINICAL & EXPERIMENTAL METASTASIS, 2017, 34 (3-4) : 222 - 222
  • [22] Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models
    Liapis, Vasilios
    Zinonos, Irene
    Labrinidis, Agatha
    Hay, Shelley
    Ponomarev, Vladimir
    Panagopoulos, Vasilios
    Zysk, Aneta
    DeNichilo, Mark
    Ingman, Wendy
    Atkins, Gerald J.
    Findlay, David M.
    Zannettino, Andrew C. W.
    Evdokiou, Andreas
    CANCER MEDICINE, 2016, 5 (03): : 534 - 545
  • [23] Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models
    Sun, Jessica D.
    Liu, Qian
    Ahluwalia, Dharmendra
    Ferraro, Damien J.
    Wang, Yan
    Jung, Don
    Matteucci, Mark D.
    Hart, Charles P.
    CANCER BIOLOGY & THERAPY, 2016, 17 (04) : 371 - 380
  • [24] Combination activity of the MEK inhibitor Pimasertib and the hypoxia-activated prodrug TH-302 in pancreatic and biliary tract tumor xenograft models
    Ma, Jianguo
    Syed, Sakeena
    Crowley, Lindsey
    Shaw, Jamie
    Ogden, Janet
    Elenbaas, Brian
    Goodstal, Samantha
    CANCER RESEARCH, 2015, 75
  • [25] Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition
    Meng, Fanying
    Bhupathi, Deepthi
    Sun, Jessica D.
    Liu, Qian
    Ahluwalia, Dharmendra
    Wang, Yan
    Matteucci, Mark D.
    Hart, Charles P.
    BMC CANCER, 2015, 15
  • [26] Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition
    Fanying Meng
    Deepthi Bhupathi
    Jessica D Sun
    Qian Liu
    Dharmendra Ahluwalia
    Yan Wang
    Mark D Matteucci
    Charles P Hart
    BMC Cancer, 15
  • [27] Pyruvate Induces Transient Tumor Hypoxia by Enhancing Mitochondrial Oxygen Consumption and Potentiates the Anti-Tumor Effect of a Hypoxia-Activated Prodrug TH-302
    Takakusagi, Yoichi
    Matsumoto, Shingo
    Saito, Keita
    Matsuo, Masayuki
    Kishimoto, Shun
    Wojtkowiak, Jonathan W.
    DeGraff, William
    Kesarwala, Aparna H.
    Choudhuri, Rajani
    Devasahayam, Nallathamby
    Subramanian, Sankaran
    Munasinghe, Jeeva P.
    Gillies, Robert J.
    Mitchell, James B.
    Hart, Charles P.
    Krishna, Murali C.
    PLOS ONE, 2014, 9 (09):
  • [28] TH-302 DNA Alkylating Agent Hypoxia-Activated Cytotoxic Prodrug Oncolytic
    Pento, J. Thomas
    DRUGS OF THE FUTURE, 2011, 36 (09) : 663 - 667
  • [29] Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer
    Sun, Jessica D.
    Liu, Qian
    Ahluwalia, Dharmendra
    Li, Wenwu
    Meng, Fanying
    Wang, Yan
    Bhupathi, Deepthi
    Ruprell, Ayesha S.
    Hart, Charles P.
    CANCER BIOLOGY & THERAPY, 2015, 16 (03) : 438 - 449
  • [30] Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models
    Stokes, Ashley M.
    Hart, Charles P.
    Quarles, C. Chad
    TOMOGRAPHY, 2016, 2 (03) : 229 - 237
12345